Patents Examined by Joseph Fischer
  • Patent number: 10507227
    Abstract: A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: Bn1-Z;??(a) Bn1-Z-Bn2; and??(b) Z-Bn1??(c) wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: December 17, 2019
    Assignee: The Hospital for Sick Children
    Inventor: Charles M. Deber
  • Patent number: 10500165
    Abstract: Purified therapeutic nanoparticles are provided herein. Such nanoparticles comprise an active pharmaceutical ingredient and human serum albumin, wherein the weight ratio of human serum albumin to the active ingredient in the therapeutic nanoparticles is from 0.01:1 to 1:1, and wherein the nanoparticles are substantially free of free human serum albumin that is not incorporated in the nanoparticles. The present disclosure also provides pharmaceutical compositions that comprise the purified therapeutic nanoparticles and are also substantially free of free human serum albumin. Methods for preparing and using the purified therapeutic nanoparticles and compositions thereof are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 10, 2019
    Inventors: Chunlei Li, Yanhui Li, Min Liang, Caixia Wang, Yajuan Wang, Shixia Wang, Dongjian Chen, Yongfeng Li
  • Patent number: 10449257
    Abstract: The present invention relates to composite hydrogels comprising at least one non-peptidic polymer and at least one peptide having the general formula: Z—(X)m—(Y)n—Z?p, wherein Z is an N-terminal protecting group; X is, at each occurrence, independently selected from an aliphatic amino acid, an aliphatic amino acid derivative and a glycine; Y is, at each occurrence, independently selected from a polar amino acid and a polar amino acid derivative; Z? is a C-terminal protecting group; m is an integer selected from 2 to 6; n is selected from 1 or 2; and p is selected from 0 or 1. The present invention further relates to methods of producing the composite hydrogels, to uses of the composite hydrogels for the delivery of drugs and other bioactive agents/moieties, as an implant or injectable agent that facilitates tissue regeneration, and as a topical agent for wound healing.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: October 22, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Yihua Loo, Andrew C. A. Wan, Michael Reithofer
  • Patent number: 10442847
    Abstract: The present invention relates to glucagon analogs and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogs suitable for use in a liquid formulation.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 15, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • Patent number: 10421795
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed under low to moderate pressure at an elevated temperature.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 24, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael P. Coleman, Allison D. Ortigosa, Mark C. Sleevi, Kartoa Chow
  • Patent number: 10398750
    Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: September 3, 2019
    Assignees: UREKA SARL, Centre National De La Recherche Scientifique (CNRS)
    Inventors: Robert H. Zimmer, Gilles Guichard, Juliette Fremaux
  • Patent number: 10351603
    Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 16, 2019
    Assignee: University of Washington
    Inventors: David Baker, Jacob B. Bale, Neil P. King, William H. Sheffler, Daniel Ellis
  • Patent number: 10335489
    Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: July 2, 2019
    Assignee: ADOCIA
    Inventor: Olivier Soula
  • Patent number: 10336803
    Abstract: This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Horng H. Chen, John C. Burnett, Jr.
  • Patent number: 10329327
    Abstract: The invention is directed to a composition comprising all or a portion of a beta-tricalcium phosphate (?-TCP) bound to all or a portion of a ?-TCP binding peptide and methods of use thereof.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: June 25, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Luis Alvarez, Linda G. Griffith, Yadir Guerrero, Linda Stockdale, Jaime Rivera
  • Patent number: 10322170
    Abstract: The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 18, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Gulle, Joris Hoefinghoff, Andreas Goessl, Katarzyna Gorna
  • Patent number: 10323062
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 18, 2019
    Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Se-Young Choung, Yeung Joon Choi
  • Patent number: 10308681
    Abstract: The present invention relates to a peptide separated from the fraction of oyster enzyme hydrolysate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrolysate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrolysate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 4, 2019
    Assignees: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Se-Young Choung, Yeung Joon Choi
  • Patent number: 10301357
    Abstract: The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 28, 2019
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Vassilios Papadopoulos, Yasaman Aghazadeh, Jinjiang Fan
  • Patent number: 10258573
    Abstract: A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 16, 2019
    Assignee: Amphastar Pharmaceuticals, Inc.
    Inventors: Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
  • Patent number: 10258074
    Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: April 16, 2019
    Assignee: Wisonsin Alumni Research Foundation
    Inventors: Denise M. Ney, Mark R. Etzel
  • Patent number: 10195255
    Abstract: The invention relates to a derivative of a GLP-1 analogue, optionally C-terminally extended, which derivative comprises a first and a second protracting moiety in the form of a C20 or C22 diacid radical, a bis-amino branched linker, and a first and a second further linker each comprising an OEG-like linker element; wherein these elements are interconnected via amide bonds and attached to a Lys residue of the GLP-1 analogue. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: February 5, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Steffen Reedtz-Runge, Per Sauerberg, Jacob Kofoed, Ingrid Pettersson, Christian W. Tornoee
  • Patent number: 10172936
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 8, 2019
    Assignee: FLOW PHARMA, INC.
    Inventors: Reid M. Rubsamen, David Earl Heckerman
  • Patent number: 10166177
    Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 1, 2019
    Assignee: Silk Therapeutics, Inc.
    Inventors: Gregory H. Altman, Rebecca L. Lacouture, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
  • Patent number: 10131717
    Abstract: The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: November 20, 2018
    Assignee: LONDON HEALTH SCIENCES CENTRE RESEARCH INC.
    Inventor: Eva Turley